

The **National Biological Information Infrastructure (NBII)** is a broad, collaborative programme to provide increased access to data and information on the nation's biological resources. The NBII links diverse, high-quality biological databases, information products, and analytical tools maintained by NBII partners and other contributors in government agencies, academic institutions, non-government organisations, and private industry.
<http://www.nbio.gov/portal/server.pt>

BIOTECCanada is the national industry-funded association representing the broad spectrum of biotech constituents including emerging, established and related service companies in the health, agricultural, and industrial sectors. It is dedicated to the sustainable commercial development of biotechnology in Canada.

The year 2007 marks the 20th year of the national association dedicated to the promotion and awareness of biotechnology and its public policy issues. Incorporated in 1987 as the Industrial Biotechnology Association of Canada, it continues to serve as the voice for industry leadership to build a sustainable environment for the community of researchers and innovators.
<http://www.biotech.ca/>

Biotechnology Information Directory Section

The World Wide Web Virtual Library is available since 1995, as a public service of Cato Research. This directory contains over 3500 links to companies, research institutes, universities, sources of information and other directories specific to biotechnology, pharmaceutical development and related fields. It places emphasis on product development and the delivery of products and services.
<http://www.cato.com/biotech/>

BIO

In 1993, when there were but a handful of biotechnology drugs on the market and the sequencing of the human genome was projected for completion somewhere around 2005, two small Washington-based biotechnology trade organisations merged to create the Biotechnology Industry Organisation, better known as BIO. One of the founding organisations, the Industrial Biotechnology Association (IBA), primarily represented larger, established companies on Capitol Hill and before federal regulatory agencies; the other, the Association of Biotechnology Companies (ABC), represented emerging companies and universities, and focused on technology transfer issues, meetings and other business development activities.

BIO united the organisations' 503 companies and 18 employees under one umbrella with a representative governing board that reserved one-third of its seats for emerging companies. The goal was to achieve within the organisation a workable balance of power between the handful of large multibillion-dollar firms that launched the first wave of biotechnology products and the hundreds of startup and mid-size firms that were at the research and development stage.

<http://www.bio.org/>

Informa Healthcare is the leading provider of business information for pharmaceutical, biotechnology, medical devices, diagnostics, instrumentation, crop protection, animal health and brewing industries.

As part of Informa plc, a wide range of news, magazines, R&D databases, books, research journals, mailing lists, contact directories and business reports is provided.

http://www.pjbpubs.com/pharmaceutical_biotechnology/index.htm

<http://www.indianbiotechobserver.com/>


Biotechnology in the United States*

In 2003, 2,196 firms were undertaking biotechnology R&D, represented 6 per cent of all R&D-active firms. These firms spent PPP\$ 14,232 million on biotechnology R&D, or 7 per cent of the total business enterprise R&D expenditures.

The majority of firms undertaking biotechnology R&D in 2003 were in the non-manufacturing sector and these constituted: 73 per cent or 1,609 firms. These firms were responsible for spending 62 per cent of all biotechnology R&D expenditures; the remainder was spent by the manufacturing sector.

The Scientific and R&D services sector in the non-manufacturing branch (North American Industry Classification System (NAICS) code 5417) had the highest share of biotechnology R&D expenditures: 36


US-based Firms undertaking Biotechnology R&D in the Business Enterprises Sector (NAICS), 2003



* Based on OECD (2006).

per cent of all biotechnology R&D expenditures. The Pharmaceuticals and Medicine sector in the manufacturing branch (NAICS code 3254) had the second largest share, with 32 per cent of total biotechnology R&D expenditures.

Ninety percent of the firms undertaking biotechnology R&D were Small and Medium-Sized Enterprises (SMEs) with fewer than 250 employees. However, these SMEs accounted for only PPP\$ 3,614 million of biotechnology R&D, or 25 per cent of the total.



US Biotechnology R&D by application field, Million PPP\$, 2001

